Solid Biosciences Inc.
NASDAQ: SLDB0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Alexander G. Cumbo
- Employees
- 100
- Headquarters
- Cambridge, United States
- IPO year
- 2018
- Market cap
- $720.7M
- Website
- https://www.solidbio.com
Loading SLDB…
Loading profile data…Frequently asked questions about SLDB
What does Solid Biosciences Inc. (SLDB) do?
Solid Biosciences Inc. is an American biotechnology firm dedicated to creating therapeutic solutions for Duchenne Muscular Dystrophy (DMD). Its most advanced experimental drug, SGT-001, is a gene transfer treatment currently in Phase I/II clinical trials, designed to encourage the production of functional dystrophin protein in patients' muscles....
Where does SLDB trade?
Solid Biosciences Inc. (SLDB) trades on the NASDAQ Global Select.
What sector is SLDB in?
Solid Biosciences Inc. (SLDB) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Solid Biosciences Inc.?
Alexander G. Cumbo is the chief executive officer of Solid Biosciences Inc. (SLDB).
Where is Solid Biosciences Inc. headquartered?
Solid Biosciences Inc. is headquartered in United States.
Does SLDB pay a dividend?
Solid Biosciences Inc. (SLDB) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did SLDB go public?
Solid Biosciences Inc. (SLDB) completed its initial public offering in 2018.